| (Values in U.S. Thousands) | Mar, 2016 | Dec, 2015 | Sep, 2015 | Jun, 2015 | Mar, 2015 |
| Sales | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 |
| Net Income Growth | unch | unch | unch | unch | unch |
Skyepharma Plc (SKYEY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
SKYEPHARMA ADR uses world-leading drug delivery technology to make good drugs even better. Combining their established pre-clinical, clinical and regulatory expertise with the capability to formulate and manufacture drugs, both for clinical studies and commercial sale, they identify and develop new therapeutics for themselves and for their partners.
Fiscal Year End Date: 12/31